Guo Yun-Ran, Liu Xin-Ming, Wang Gui-Xia
Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun 130000, Jilin Province, China.
World J Diabetes. 2023 Feb 15;14(2):120-129. doi: 10.4239/wjd.v14.i2.120.
Exposure to proton pump inhibitors (PPIs) has been reported to have a potential role in the development of diabetes.
To determine the association between PPIs and diabetes.
This meta-analysis is registered on PROSPERO (CRD42022352704). In August 2022, eligible studies were identified through a comprehensive literature search. In this study, odds ratios were combined with 95% confidence intervals using a random-effects model. The source of heterogeneity was assessed using sensitivity analysis and subgroup analysis. The publication bias was evaluated using Egger's test and Begg's test.
The meta-analysis included 9 studies with a total of 867185 participants. Results showed that the use of PPIs increased the risk of diabetes (odds ratio = 1.23, 95% confidence interval: 1.05-1.43, = 9, I = 96.3%). Subgroup analysis showed that geographic location and study type had significant effects on the overall results. Both Egger's and Begg's tests showed no publication bias ( > 0.05). Sensitivity analysis also confirmed the stability of the results.
The results of this study indicated that the use of PPIs was related to an increased risk of diabetes. However, more well-designed studies are needed to verify these results in the future.
据报道，使用质子泵抑制剂（PPIs）可能在糖尿病的发生发展中起作用。
确定PPIs与糖尿病之间的关联。
本荟萃分析已在国际前瞻性系统评价注册库（PROSPERO，注册号：CRD42022352704）登记。2022年8月，通过全面的文献检索确定符合条件的研究。在本研究中，采用随机效应模型合并比值比及95%置信区间。使用敏感性分析和亚组分析评估异质性来源。采用Egger检验和Begg检验评估发表偏倚。
该荟萃分析纳入9项研究，共867185名参与者。结果显示，使用PPIs会增加患糖尿病的风险（比值比 = 1.23，95%置信区间：1.05 - 1.43，P = 0.009，I² = 96.3%）。亚组分析表明，地理位置和研究类型对总体结果有显著影响。Egger检验和Begg检验均显示无发表偏倚（P > 0.05）。敏感性分析也证实了结果的稳定性。
本研究结果表明，使用PPIs与糖尿病风险增加有关。然而，未来需要更多设计良好的研究来验证这些结果。
